Challenge to "Injection Needles That Do Not Damage Cells" - Algovision Technologies Develops New Technology Supporting Regenerative Medicine - A New Era of Inner Surface Processing for Injection Needles.

"Algovision Technologies Co., Ltd. (Headquarters: Kyoto Prefecture, CEO: Shoichi Tachibana) has developed a new technology that utilizes its flagship product, fluid polishing equipment, to smoothly polish the inner surface of injection needles used in regenerative medicine.
This has revealed the potential to reduce the 'risk of cell damage within the injection needle,' which has been a challenge when delivering cells directly into a patient's body, and it is expected to further accelerate the practical application of regenerative medicine." - A press release has been distributed.

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration